General presentation of Novo Nordisk
Still with the objective of increasing your knowledge about Novo Nordisk we will now present information about this company with details pertaining to its activities and sources of revenue that will assist you in better understanding the challenges it faces and its possibilities for growth.
Novo Nordisk is a Danish company specialised in the creation, production and sale of pharmaceutical products. To better understand its activities we can divide them into a number of sectors according to the turnover they generate and how they do so:
- The production and sale of treatment products for diabetes and obesity that represent the majority of the group’s income and generate nearly 84.3% of its turnover.
- In second position we find the activities related to haemophilia treatment products that generate 8.4% of the group’s turnover, notably with the protein injections.
- Then we have the production and sale of growth hormones representing 6% of the turnover of this company which are destined for children that require growth deficiency treatment.
- And finally we find the hormonal substitute products including those for menopause and osteoporosis prevention that represent 1.3% of the company’s turnover.
It can also be advantageous to know the geographical distribution of this company’s income. In fact, 19.1% of its revenue is currently generated in Europe, 47.1% in the United States, 2.5% in North America, 11.5% in Africa, the Middle East and Oceania, 10.5% in China, 5.3% in Japan and Korea and 4% in Latin America.
72% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on Plus500